Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Stride To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Stride between October 22, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh […]
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Sprouts to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Sprouts between June 4, 2025 and October 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh
As 2026 begins, many people are setting goals to live healthier, stay active, and take control of their well-being. For those who rely on supplemental oxygen, maintaining optimal respiratory health is a key part of achieving these resolutions. VARON is supporting these efforts with the launch of the VP-8 Lite Portable Oxygen Concentrator–a lightweight, reliable,
NEW YORK CITY, NY / ACCESS Newswire / January 11, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Firefly Aerospace Inc. ("Firefly" or the "Company") (NASDAQ:FLY) and certain officers.�� The class action, filed in the United States District Court for the Western District of Texas, and docketed under 25-cv-01812,
(NASDAQ:ZYME), Positive Phase 3 HERIZON-GEA-01 results for Ziihera(R) (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe, Japan, and China Company well-positioned to execute new strategy compounding long-term
(NasdaqGM:ESPR), – Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – -Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash
(NYSE:TEVA),(TASE:TEVA.TA),(TASE:TEVA), TEL AVIV, Israel, Jan. 11, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will present its ongoing transformation and expected growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference. Teva's President and Chief Executive Officer, Richard Francis, will meet with investors and present the Company's milestones achieved
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) GlobeNewswire January 11, 2026
Zymeworks Outlines Strategic Priorities and Outlook for 2026 GlobeNewswire January 11, 2026 Positive Phase 3 HERIZON-GEA-01 results for Ziihera(R) (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone payments eligible to be earned related to regulatory approvals of Ziihera in GEA in the United States, Europe,
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 11, 2026 – Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – -Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year